izpis_h1_title_alt

Zinc pyrithione is a potent inhibitor of PL$^{Pro}$ and cathepsin L enzymes with ex vivo inhibition of SARS-CoV-2 entry and replication
ID Kladnik, Jerneja (Author), ID Dolinar, Ana (Author), ID Kljun, Jakob (Author), ID Perea, David (Author), ID Grau-Expósito, Judith (Author), ID Genescà, Meritxell (Author), ID Novinec, Marko (Author), ID Buzon, Maria J. (Author), ID Turel, Iztok (Author)

.pdfPDF - Presentation file, Download (1,91 MB)
MD5: DA088CD61DFA54A238FA99B4E3C69B68
URLURL - Source URL, Visit https://www.tandfonline.com/doi/full/10.1080/14756366.2022.2108417 This link opens in a new window

Abstract
Zinc pyrithione (1a), together with its analogues 1b–h and ruthenium pyrithione complex 2a, were synthesised and evaluated for the stability in biologically relevant media and anti-SARS-CoV-2 activity. Zinc pyrithione revealed potent in vitro inhibition of cathepsin L (IC$_{50}$=1.88 ± 0.49 µM) and PL$^{Pro}$ (IC$_{50}$=0.50 ± 0.07 µM), enzymes involved in SARS-CoV-2 entry and replication, respectively, as well as antiviral entry and replication properties in an ex vivo system derived from primary human lung tissue. Zinc complexes 1b–h expressed comparable in vitro inhibition. On the contrary, ruthenium complex 2a and the ligand pyrithione a itself expressed poor inhibition in mentioned assays, indicating the importance of the selection of metal core and structure of metal complex for antiviral activity. Safe, effective, and preferably oral at-home therapeutics for COVID-19 are needed and as such zinc pyrithione, which is also commercially available, could be considered as a potential therapeutic agent against SARS-CoV-2.

Language:English
Keywords:antiviral agents, SARS-CoV-2, inhibition, pyrithione, zinc
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FKKT - Faculty of Chemistry and Chemical Technology
Publication status:Published
Publication version:Version of Record
Year:2022
Number of pages:Str. 2158-2168
Numbering:Vol. 37, no. 1
PID:20.500.12556/RUL-145390 This link opens in a new window
UDC:546.47:61:577
ISSN on article:1475-6366
DOI:10.1080/14756366.2022.2108417 This link opens in a new window
COBISS.SI-ID:118456067 This link opens in a new window
Publication date in RUL:20.04.2023
Views:343
Downloads:148
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Journal of enzyme inhibition and medicinal chemistry
Shortened title:J. enzyme inhib. med. chem.
Publisher:Taylor & Francis
ISSN:1475-6366
COBISS.SI-ID:512255001 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:protivirusna zdravila, SARS-COV-2, inhibicija, pirition, cink

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0175
Name:Napredna anorganska kemija

Funder:Other - Other funder or multiple funders
Funding programme:Government of Catalonia, Health Department
Project number:DGRIS 1_5

Funder:Other - Other funder or multiple funders
Funding programme:Fundació La Marató TV3
Project number:202104FMTV3

Funder:Other - Other funder or multiple funders
Funding programme:Fundació La Marató TV3
Project number:202112FMTV3

Funder:Other - Other funder or multiple funders
Funding programme:Spain, Health Institute Carlos III, Miguel Servet Program
Project number:CP17/00179

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back